0.49% +0.81

애브비 (ABBV)

개요 뉴스 가격 이력 옵션 체인 Financials ABBV 왜 하락? 토론 예측 배당 이력

왜 Abbvie Inc (ABBV) 주가가 하락하고 있습니까?

2024-04-26 거래 세션 동안 Abbvie Inc(ABBV) 주식이 5.36% 하락한 것을 확인했습니다. 이는 정상적인 변동성이나 다양한 내부 및 외부 요인에 의한 것일 수 있지만, 상황을 적극적으로 모니터링하고 있으며 최대한 빨리 적시에 업데이트를 제공하도록 하겠습니다!

2024-04-04:

Abbvie (ABBV) stock dropped by 5.32% following the company's revision of its full-year and Q1 guidance, reflecting an unfavorable impact on earnings. This marked the biggest intraday decline in more than five months for the North Chicago-based pharma giant.

Revised Guidance: AbbVie revised its full-year and Q1 2024 guidance for adjusted diluted earnings to $10.97–$11.17 and $2.18–$2.22 per share, respectively. This adjustment accounts for acquired in-process R&D and milestones expenses.
Impact on Earnings: The company stated that $164 million in acquired IPR&D and milestones expense for Q1 2024 would have a $0.08 unfavorable impact on GAAP and non-GAAP diluted earnings per share for the quarter.
Previous Guidance Adjustment: In February, AbbVie lowered its Q1 adjusted diluted EPS guidance to $2.26–$2.30, including a $0.42 per share dilutive impact related to its Immunogen acquisition and pending buyout deal with Cerevel Therapeutics (CERE). Despite this, the company reaffirmed its full-year adjusted diluted EPS guidance at $11.05–$11.25 for 2024.
Analysts' View: The correction made to the story clarified AbbVie's full-year earnings outlook, highlighting the importance of accurate financial reporting and its impact on stock performance.